Abstract:Objective To investigate the function of monocyte chemoattractant protein-1 (MCP-1) in prostate cancer. Methods Expression levels of MCP-1 and angiotensin II type 1 receptor (AT1R) in prostate cancer cell lines LNCaP, C4-2 and C4-2AT6 were detected by the immunohistochemistry assay. Prostate cancer cell lines were treated with CV11974 (the AT1R inhibitor), LY294002 (the PI3K inhibitor) or TCV116 (the AT1R inhibitor). ELISA assay, Western blotting and immunohistochemistry were performed for measurement of several proteins including MCP- 1, phosphorylated Akt (p-Akt), CD68 and F4/80+. Results MCP-1 and AT1R were expressed in the prostate cancer cell line LNCaP, C4-2 and C4-2AT6 with the highest expression in C4-2AT6. In the C4-2 and C4-2AT6 cell line, Ang II increased the MCP-1 production (P < 0.05), which was reversed by CV11974 and LY294002 (P < 0.05). In C4- 2AT6 cell line, Ang II increased the phosphorylation of Akt (P < 0.05), which was reversed by LY294002 (P < 0.05). Treatment of TCV116 decreased the expression level of MCP-1 and CD68. Expression of MCP-1 and CD68 was positively correlated with the malignancy which was suggested by Gleason score. Conclusion MCP-1 plays an important role in the malignant progression of prostate cancer via AT1R-PI3K/Akt signaling pathway.